| Literature DB >> 33296446 |
Shahideh Amini1, Arezou Ghasemi2, Mohammad Solduzian1, Besharat Rahimi3, Kazem Heidari4, Molouk Hadjibabaie1, Mona Kargar4.
Abstract
BACKGROUND: Inhalers are the mainstay of treatment for patients suffering from chronic obstructive pulmonary disease. However, incorrect inhaler technique is a considerable challenge.Entities:
Keywords: Chronic Obstructive Pulmonary Disease Assessment Test; dry powder inhalers; metered dose inhalers; pulmonary disease chronic obstructive; quality of life
Year: 2020 PMID: 33296446 PMCID: PMC7691547 DOI: 10.1016/j.curtheres.2020.100608
Source DB: PubMed Journal: Curr Ther Res Clin Exp ISSN: 0011-393X
Distribution of disease status and treatment-related factors among patients using different devices.
| Characteristic | Inhaler | Total | ||||
|---|---|---|---|---|---|---|
| pMDI | DPI | pMDI + spacer | pMDI + DPI | |||
| Inhaler users | 57 (32.6) | 38 (21.7) | 19 (10.9) | 61 (34.8) | 175 (100) | |
| Age | 59.4 (9.9) | 59.2 (8.6) | 62.4 (9.3) | 59.6 (11.3) | 59.8 (10.1) | |
| Age range (y) | 43-85 | 42-75 | 45-84 | 42-85 | 42-85 | |
| Male sex | 35 (61.4) | 21 (55.3) | 7 (36.8) | 38 (62.3) | 101 (57.7) | |
| Education | Illiterate | 26 (45.6) | 14 (36.8) | 13 (68.4) | 23 (37.7) | 76 (43.4) |
| Under diploma | 26 (45.6) | 15 (39.5) | 5 (26.3) | 25 (41.0) | 71 (40.6) | |
| Diploma | 3 (5.3) | 7 (18.4) | 0 | 11 (18.0) | 21 (12) | |
| Academic | 2 (3.5) | 2 (5.3) | 1 (5.3) | 2 (3.3) | 7 (4) | |
| GOLD stage | 1 | 28 (49.1) | 21 (55.3) | 5 (26.2) | 17 (27.9) | 71 (40.6) |
| 2 | 19 (33.3) | 11 (28.9) | 9 (47.4) | 32 (52.4) | 71 (40.6) | |
| 3 | 7 (12.3) | 5 (13.2) | 4 (21.1) | 9 (14.8) | 25 (14.3) | |
| 4 | 3 (5.3) | 1 (2.6) | 1 (5.3) | 3 (4.9) | 8 (4.5) | |
| CAT score | 10.2 (7.0) | 8.3 (7.8) | 13.8 (9.4) | 9.6 (7.9) | 10.0 (7.9) | |
| CAT score reange | 0–10 | 33 (57.9) | 26 (68.4) | 9 (47.4) | 37 (60.7) | 105 (60) |
| 11–20 | 16 (28.1) | 8 (21.1) | 5 (26.3) | 19 (31.1) | 48 (27.4) | |
| 21–30 | 8 (14.0) | 3 (7.9) | 4 (21.0) | 4 (6.6) | 19 (10.8) | |
| 31–40 | 0 | 1 (2.6) | 1 (5.3) | 1 (1.6) | 3 (1.7) | |
| No. of inhalers | 1 | 8 (14.0) | 9 (23.7) | 1 (5.2) | 0 | 18 (10.3) |
| 2 | 33 (57.9) | 26 (68.4) | 9 (47.4) | 42 (68.9) | 110 (62.9) | |
| 3 | 15 (26.3) | 3 (7.9) | 9 (47.4) | 18 (29.5) | 45 (25.7) | |
| Duration of inhaler use | ≤1 mo | 1 (1.8) | 0 | 0 | 4 (6.6) | 5 (2.9) |
| 1–6 mo | 23 (40.4) | 18 (47.4) | 7 (36.8) | 24 (39.3) | 72 (41.1) | |
| 6–12 mo | 16 (28.1) | 9 (23.6) | 3 (15.8) | 21 (34.4) | 49 (28) | |
| 1–3 y | 7 (12.3) | 7 (18.4) | 7 (36.8) | 8 (13.1) | 29 (16.6) | |
| 3–5 y | 5 (8.7) | 2 (5.3) | 0 | 0 | 7 (4) | |
| >5 y | 5 (8.7) | 2 (5.3) | 2 (10.6) | 4 (6.6) | 13 (7.4) | |
CAT = Chronic Obstructive Pulmonary Disease Assessment Test; DPI = dry powder inhaler, GOLD = Global Initiative for Chronic Obstructive Lung Disease; pMDI = pressurized metered-dose inhaler.
Values are presented as n (%).
Values are presented as mean (SD).
Evaluation of association between different variables and Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score.
| Variable | No. of patients | CAT score | ||
|---|---|---|---|---|
| Sex | Male | 10 | 9.8 (7.5) | 0.88 |
| Female | 74 | 10.1 (8.3) | ||
| GOLD stage | 1 | 71 | 8.0 (6.9) | 0.002 |
| 2 | 71 | 10.4 (7.9) | ||
| 3 | 25 | 11.1 (7.2) | ||
| 4 | 8 | 20 (9.4) | ||
| Education | Illiterate | 76 | 10.8 (8.4) | 0.39 |
| Under diploma | 71 | 9.6 (7.6) | ||
| Diploma | 21 | 7.5 (5.5) | ||
| Academic | 7 | 12.9 (9.3) | ||
| Duration of inhaler use | ≤1 mo | 5 | 12.2 (10.4) | 0.40 |
| 1–6 mo | 72 | 8.8 (7.0) | ||
| 6–12 mo | 49 | 10.2 (7.9) | ||
| 1–3 y | 29 | 10.3 (9.5) | ||
| 3–5 y | 7 | 12.1 (8.8) | ||
| >5 y | 13 | 12.8 (6.4) | ||
| Smoking | Current smoker | 82 | 9.8 (7.9) | 0.85 |
| Exsmoker | 62 | 10.3 (7.9) | ||
| Nonsmoker | 31 | 9.9 (7.8) | ||
GOLD = Global Initiative for Chronic Obstructive Lung Disease.
Values are presented as mean (SD).
Characteristics of patients with at least 1 error and those with >30% incorrect rate in inhaler technique.
| Characteristic | % of error (Mean [SD]) | At least 1 error | >30% error rate | |||
|---|---|---|---|---|---|---|
| n (%) | n (%) | |||||
| Sex | Male (n = 101) | 28.3 (17.8) | 98 (97.0) | 0.91 | 40 (40) | 0.51 |
| Female (n = 74) | 27.6 (15.3) | 72 (97.3) | 26 (35.1) | |||
| Education | Illiterate (n = 76) | 32.0 (16.7) | 75 (98.7) | 0.24 | 38 (50) | 0.024 |
| Under diploma (n = 71) | 27.1 (16.3) | 69 (97.2) | 22 (31.4) | |||
| Diploma (n = 21) | 20.6 (15.6) | 19 (90.5) | 5 (23.8) | |||
| Academic (n = 7) | 16.5 (13.8) | 7 (100) | 1 (14.3) | |||
| Duration of inhaler use | ≤1 mo (n = 5) | 17.9 (11.3) | 5 (100) | 0.90 | 0 | 0.37 |
| 1–6 mo (n = 72) | 26.6 (16.3) | 70 (97.2) | 25 (35.2) | |||
| 6–12 mo (n = 49) | 27.2 (15.8) | 48 (98.0) | 18 (36.7) | |||
| 1–3 y (n = 29) | 29.6 (18.8) | 28 (96.6) | 13 (44.8) | |||
| 3–5 y (n = 7) | 40.7 (12.7) | 7 (100) | 4 (57.1) | |||
| >5 y (n = 13) | 32.2 (19.4) | 12 (92.3) | 6 (46.2) | |||
| GOLD stage | 1 (n = 71) | 26.2 (17.9) | 68 (95.8) | 0.69 | 23 (32.4) | 0.47 |
| 2 (n = 71) | 28.2 (16.3) | 69 (97.2) | 27 (38.6) | |||
| 3 (n = 25) | 31.5 (15.2) | 25 (100) | 12 (48) | |||
| 4 (n = 8) | 31.7 (14.3) | 8 (100) | 4 (50) | |||
| CAT | 0–10 (n = 105) | 26.2 (16.5) | 100 (95.2) | 0.33 | 10 (9.5) | < 0.001 |
| 11–20 (n = 48) | 27.9 (15.9) | 48 (100) | 5 (10.4) | |||
| 21–30 (n = 19) | 37.9 (18.7) | 19 (100) | 9 (47.4) | |||
| 31–40 (n = 3) | 29.6 (11.8) | 3 (100) | 0 | |||
CAT = Chronic Obstructive Pulmonary Disease Assessment Test; GOLD = Global Initiative for Chronic Obstructive Lung Disease.
Figure 1Frequency of errors made by patients in each step of the pressurized metered-dose inhaler (pMDI) checklist.
Figure 4Frequency of error made by patients in each step of the Revolizer checklist.
Average errors in patients using different inhalers.
| Inhaler device | No. of patients | Mean % of errors (SD) | Without error |
|---|---|---|---|
| pMDI | 57 | 38.9 (15.8) | 0 (0) |
| pMDI + spacer | 19 | 42.3 (13.9) | 0 (0) |
| DPI | 38 | 15.4 (10.5) | 2 (5.3) |
| pMDI + DPI | 61 | 21.3 (11.6) | 3 (4.9) |
DPI = dry powder inhaler; pMDI = pressurized metered-dose inhaler.